The coronavirus could perchance perchance hold quashed plans to socialize and stroll the canals of Amsterdam while at this year’s European Society of Cardiology (ESC) Congress, however organizers are promising a historical digital expertise that could “as soon as over again, be a celebration of discovery and ground-breaking science.”
“My message — if I want to grab simplest one direct why ESC 2020 will be a historical event — is that the doctor working on the Cleveland Medical institution, who used to be planning to attend this year in Amsterdam, as well to the colleague in a bush sanatorium in Uganda, who would hold never hold dreamed to be piece of the ESC Congress, every can hold for the first time the identical get entry to on the identical time to knowledge shared on the worldwide leading cardiovascular assembly,” Marco Roffi, MD, co-chair of the scientific program, told theheart.org | Medscape Cardiology.
Taking a page from the American Faculty of Cardiology, which spot the virtual bar early within the pandemic with its highly interactive ACC 2020, ESC is taking some 80 Hot Line, clinical be conscious options, and special sessions live with request-and-acknowledge interactions and panel discussions.
The most up-to-date COVID-19 research and 4 new guideline paperwork — including suggestions on atrial fibrillation (AF), non-ST-segment elevation acute coronary syndromes, sports actions cardiology and exercise in patients with cardiovascular illness, and grownup congenital heart illness — will be featured on the ESC Congress 2020, scheduled for August 29 to September 1.
Presentations will be shorter and sessions more focused, however more than 500 scientific and tutorial sessions will be streamed as well to to more than 4000 abstracts on hand live or on quiz as stout shows or e-posters, acknowledged Roffi, College Clinical institution of Geneva, Switzerland.
To pull off the virtual event, a digital studio in Amsterdam will host tons of of key thought leaders, and ESC employed more than 1000 satellite tv for pc studios across the field to amass contributions from scientists and consultants with the serve of 70 within the befriend of-the-scenes consultants.
Nevertheless, a “strategic decision” used to be made to provide free get entry to to the event and its explain for 30 days — a methodology that has attracted some 58,000 registrants so some distance, up from a document 32,000 attendees in the end year’s congress in Paris, Roffi acknowledged.
“Obviously, the earnings is per chance not the identical as a bodily congress, however we felt there used to be too grand at stake to map a compromise,” he acknowledged. “We mediate we are the leaders in cardiovascular conferences within the bodily ones and we would like to retain this spot even within the new technology. And we mediate this is the beginning of a brand new technology in no matter develop will be.”
Hot Line Intervals 1-3, Saturday (14: 00 CEST)
The Hot Line sessions will characteristic 13 clinical trials and kick off with EMPEROR-Reduced, which when in contrast the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) added to regular care in patients with heart failure with diminished ejection fraction (HFrEF), with and with out diabetes.
Eli Lilly and Boehringer Ingelheim already launched the trial met its composite critical endpoint of cutting back cardiovascular (CV) loss of life or HF hospitalization threat however the critical aspects will be critical given the SGLT2 inhibitors’ like a flash shift beyond diabetes to HF and power kidney illness (CKD).
Outcomes supplied at ESC 2019 from the landmark DAPA-HF trial ended in the current new indication for dapagliflozin (Farxiga, AstraZeneca) for HFrEF within the absence of diabetes. Novel knowledge will be released in a Sunday Hot Line session searching on the SGLT2 inhibitor among diabetic and nondiabetic CKD patients in DAPA-CKD, which used to be halted early on myth of overwhelming efficacy.
Because the indication superior, the SGLT2 inhibitors was essentially cardiovascular illness medication, Roffi acknowledged, “so the full cardiologists will want to change into conversant in these agents.”
Hot Line 2 will gaze on the oral cardiac myosin inhibitor mavacamten as an alternative to surgical treatment or percutaneous interventions to treat obstructive hypertrophic cardiomyopathy (HCM). The first-in-class investigational agent is believed to cut back the hypercontractility attribute of HCM by inhibiting indecent actin-myosin imperfect-bridges, and it showed promise within the current piece 2 dose-finding MAVERICK HCM trial.
Investigators are anticipated to flesh out critical aspects from the 251-affected person piece 3 EXPLORER-HCM trial, which reported functional and symptomatic beneficial properties with as soon as-on each day basis dosing in high-line outcomes released by developer MyoKardia.
“Here’s in actuality a innovative technique to treat — with any luck efficiently — this very advanced illness,” Roffi acknowledged.
Rounding out the day is the EAST-AFNET 4 trial, which has been practically 10 years within the making and examined whether or not early rhythm spend watch over with antiarrhythmic medication and catheter ablation can forestall adverse outcomes in patients with AF when in contrast with bizarre care on my own in accordance with the ESC 2010 AF remedy options.
Hot Line Intervals 4-6, Sunday (14: 00 CEST)
Hot Line 4 sides the ATPCI sight inspecting the addition of the oral antianginal agent trimetazidine to regular of care in 6007 patients with angina after current a hit percutaneous coronary intervention.
“Here’s a predicament that now we hold each day within the cath lab after we carry out a TAVI because now we hold in front of us patients who, by definition, are at excessive bleeding threat, are ragged, and hold comorbidities equivalent to renal insufficiencies,” Roffi acknowledged. “I admire this very grand because or not it is a in actuality useful sight. No matter the response will be of this sight, this could occasionally influence clinical be conscious.”
Hot Line 6 is dedicated to the PARALLAX trial evaluating sacubitril/valsartan (Entresto, Novartis) with individualized clinical therapy in 2569 heart failure with preserved ejection fraction (HFpEF) patients. The critical outcomes are 12-week switch in N-terminal pro-brain natriuretic peptide and 24-week switch in 6-minute stroll distance.
Hot Line Intervals 7-9, Monday (14: 00 CEST)
The next day begins with the timely topic of inflammation with the LoDoCo2 trial, wherein 5522 patients with true coronary artery illness had been randomized to low-dose colchicine 0.5 mg on each day basis or placebo on high of optimum clinical therapy. The critical composite endpoint is CV loss of life, myocardial infarction (MI), ischemic stroke, and ischemia-pushed revascularization.
Extra colchicine knowledge additionally will be supplied in a unimaginative-breaking science session on Saturday that involves the Australian COPS trial in acute coronary syndromes and new analyses from COLCOT, which demonstrated a 23% reduction within the threat of first ischemic CV occasions following an MI however no mortality profit. The low-value anti-inflammatory drug is additionally being tested within the colossal 6000-affected person piece 3 Colchicine Coronavirus SARS-CoV-2 (COLCORONA) trial, anticipated to be accomplished by the conclude of September.
Hot Line 8 switches gears with the originate-designate randomized HOME-PE trial evaluating outpatient management of pulmonary embolism (PE) in 1975 purchase patients in accordance with either the simplified Pulmonary Embolism Severity Index (PESI) score, featured in essentially the most current ESC acute PE options, or the HESTIA requirements, developed within the HESTIA sight. The event-pushed critical conclude point is the composite of recurrent venous thromboembolism, predominant bleeding, and all-trigger loss of life at 30 days.
Final up on Monday is a brand new prognosis on the outcomes of decreasing blood strain for prevention of CV occasions across varied BP ranges from the BPLTTC, which is the finest resource of affected person-stage randomized clinical trial knowledge, at more than 350,000 patients.
Tuesday Hot Line Intervals 10-12 (14: 00 CEST)
The closing day of the Congress ends with bang, with the randomized BRACE-CORONA trial inspecting the create of fixed or suspending angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in 700 patients with SARS-CoV-2 infection.
Though loads of cardiovascular societies including ESC recommend continuation of renin-angiotensin-aldosterone draw (RAAS) antagonists in COVID-19 patients, randomized knowledge are lacking and patients were rattled by early observations suggesting that ACE2 upregulation from RAAS antagonists could perchance perchance amplify the threat of developing excessive COVID-19.
“BRACE-CORONA will acknowledge the request that every person’s been asking, whether or not or not you’re going to also mute continue ARBs and ACE inhibitors in COVID-19 patients. Here’s a randomized trial and we are all very eager on it,” Roffi acknowledged.
COVID-19 will additionally be discussed in a unimaginative-breaking science session on Sunday and in three switch Q&A sessions scattered over the 4 days.
Rounding out the final Hot Line session is IMPACT-AFib, a claims database prognosis of early vs delayed tutorial interventions to boost oral anticoagulation spend in a whopping 80,000 patients with AF, and REALITY, a grand-critical value-effectiveness prognosis of liberal vs restrictive transfusion methods in 630 patients with acute MI and anemia.